Crossman L C, O'Hare T, Lange T, Willis S G, Stoffregen E P, Corbin A S, O'Brien S G, Heinrich M C, Druker B J, Middleton P G, Deininger M W N
Oregon Health & Science University Cancer Institute, Portland, OR, USA.
Leukemia. 2005 Nov;19(11):1859-62. doi: 10.1038/sj.leu.2403935.
We have identified a gene polymorphism (K247R) within or close to the P-loop of BCR-ABL, which leads to the substitution of arginine for lysine. We investigated the allelic frequency of K247R by screening 157 CML patients and 213 healthy blood donors with conventional sequencing, restriction enzyme digest and single strand conformational polymorphism analysis, and found the arginine allele to be rare. Three out of five CML patients with the arginine allele of K247R failed to achieve a major cytogenetic response to imatinib, suggesting that the arginine allele may have reduced sensitivity. However, despite K247R's position in or near to the P-loop, biochemical and cellular assays of imatinib and dasatinib sensitivity showed no alteration compared to wild type. Clinicians should be aware that possession of the arginine allele of K247R does not reflect a mutation that necessitates a change in the therapeutic strategy, unless there are other signs of inadequate response to drug.
我们在BCR-ABL的P环内或其附近鉴定出一种基因多态性(K247R),该多态性导致赖氨酸被精氨酸替代。我们通过常规测序、限制性酶切和单链构象多态性分析对157例慢性粒细胞白血病(CML)患者和213名健康献血者进行筛查,以研究K247R的等位基因频率,发现精氨酸等位基因很罕见。携带K247R精氨酸等位基因的5例CML患者中有3例未达到对伊马替尼的主要细胞遗传学反应,这表明精氨酸等位基因可能降低了敏感性。然而,尽管K247R位于P环内或其附近,但与野生型相比,伊马替尼和达沙替尼敏感性的生化及细胞分析未显示出改变。临床医生应意识到,除非有其他药物反应不足的迹象,否则携带K247R精氨酸等位基因并不意味着存在需要改变治疗策略的突变。